Transitional cell carcinoma of the ovary (Review)

Ichigo, Satoshi; Matsunami, Kazutoshi; Murase, Takayuki; Ikeda, Tsuneko; Imai, Atsushi

doi:10.3892/ol.2011.453

Cited by 22 publications

(28 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Microscopically, it shows undulating, diffuse, insular, and trabecular growth patterns. 4 Our case showed large blunt papillae, which was also observed by Eichhorn and Young 5 in 63% of their cases. Primary TCC of ovary needs to be differentiated from metastatic TCC from urinary bladder.…”

Section: Discussionsupporting

confidence: 60%

Bilateral Ovarian Transitional Cell Carcinoma

Pilli¹,

Davanagere²,

Suranagi³

et al. 2017

Journal of SAFOMS

View full text Add to dashboard Cite

Ovarian cancer accounts for 6% of all cancers among women. The majority (85-90%) of malignant ovarian tumors are epithelial. Transitional cell carcinoma (TCC) has been described as a primary ovarian carcinoma in which definite urothelial features are present, but no benign, metaplastic, and/or proliferating Brenner tumor can be identified. It accounts for 1 to 2% of all ovarian tumors. Bilateral involvement is still rare. It is reported to be chemosensitive and has better prognosis than other types of common epithelial tumors of the ovary. Here, we report a rare case of bilateral TCC of the ovary managed by staging operation, followed by postoperative chemotherapy.

show abstract

Section: Discussionsupporting

confidence: 60%

Bilateral Ovarian Transitional Cell Carcinoma

Pilli¹,

Davanagere²,

Suranagi³

et al. 2017

Journal of SAFOMS

View full text Add to dashboard Cite

show abstract

“…Histopathological examination is the first method used in the diagnosis and differentiation of EOC heterogeneous tumors and in the separation of closely related cases (Ichigo et al 2012). EOC tumors are generally classified into histological subgroups depending on their aggressive behavior and their malignant potential (D'Andrilli et al 2008;Lalwani et al 2011).…”

Section: Discussionmentioning

confidence: 99%

Immunohistological Insight into the Correlation between Neuropilin-1 and Epithelial-Mesenchymal Transition Markers in Epithelial Ovarian Cancer

Adham

Al-Harrasi

Haddabi

et al. 2014

J Histochem Cytochem.

View full text Add to dashboard Cite

The mechanism by which neuropilin-1 (NRP-1) induces malignancy in Epithelial Ovarian Cancer (EOC) is still unknown. This study is the first to demonstrate the relationship between NRP-1 expression and EMT markers vimentin, N-cadherin, E-cadherin and Slug. We used tissue microarrays containing the three main subtypes of EOC tumors: serous, mucinous cystadenocarcinoma and endometrioid adenocarcinoma and representative cases retrieved from our pathology archives. Immunohistochemistry was performed to detect the expression levels and location of NRP-1 and the aforementioned EMT proteins. NRP-1 was mainly expressed on cancer cells but not in normal ovarian surface epithelium (OSE). The Immunoreactive Scoring (IRS) values revealed that the expression of NRP-1, Slug and E-cadherin in the malignant subtypes of ovarian tissues was significantly higher (5.18 ± 0.64, 4.84 ± 0.7, 4.98 ± 0.68, respectively) than their expression in the normal and benign tissues (1.04 ± 0.29, 0.84 ± 0.68, 1.71 ± 0.66, respectively), with no significant differences among the studied subtypes. Vimentin was expressed in the cancer cell component of 43% of tumors and it was exclusively localized in the stroma of all mucinous tumors. The Spearman’s rho value indicated that NRP-1 is positively related to the EMT markers E-cadherin and Slug. This notion might indicate that NRP-1 is a partner in the EMT process in EOC tumors.

show abstract

“…TCCs represent a small percentage of ovarian cancers, and have been demonstrated to be a distinct group, with differing histological and immunohistological aspects. However, the clinical presentation of TCC is similar to that of other types of ovarian carcinoma (1). Its typical symptoms include abdominal pain, abdominal distension and pelvic masses, and serum CA-125 is usually positive.…”

Section: Introductionmentioning

confidence: 93%

Good survival in a patient with recurrent transitional cell carcinoma of the ovary: A case report of PET-CT for detection and follow-up

Wang

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. Transitional cell carcinoma (TCC) of the ovary is a rare subtype of epithelial ovarian cancer. The present study reports the case of a 55-year-old patient from The Affiliated Tumor Hospital of Harbin Medical University (Harbin, Heilongjiang, China) who underwent successful surgery for recurrence of a TCC of the ovary with rectum metastases following the initial surgery and chemotherapy. Positron emission tomography/computed tomography (PET-CT) was used in the pre-operative detection of the tumor and the post-operative follow-up of the patient. To date, the patient has experienced 8 years of disease-free survival. The aim of the present study was to convey the good survival rate of the patient following recurrent TCC of the ovary, and the role of PET-CT in detection and follow-up, in order to aid in the future selection of appropriate diagnostic methods and therapies for this disease. IntroductionTransitional cell carcinoma (TCC) of the ovary, in contrast to that of the bladder, is a rare entity and therefore, studies of recurrence are few in number. The true incidence of TCC of the ovary remains unclear. TCCs represent a small percentage of ovarian cancers, and have been demonstrated to be a distinct group, with differing histological and immunohistological aspects. However, the clinical presentation of TCC is similar to that of other types of ovarian carcinoma (1). Its typical symptoms include abdominal pain, abdominal distension and pelvic masses, and serum CA-125 is usually positive. The primary therapeutic approach for TCC is surgery and chemotherapy, and the consequent patient outcomes are an improvement on those of other types of common epithelial ovarian cancers (2). Case reportIn 2004, a 55-year-old female was diagnosed with International Federation of Gynecology and Obstetrics stage IIIc (3) TCC of the ovary in the Department of Gynecology in The Affiliated First Hospital of Harbin Medical University (Harbin, Heilongjiang, China) and underwent satisfactory cytoreductive surgery consisting of hysterectomy, bilateral salpingo-oophorectomy, appendectomy and partial omentectomy. The post-surgical pathological evaluation revealed that the the ovarian tumor was TCC, grade 3, with involvement of the appendix. Subsequently, seven cycles of chemotherapy were administered, consisting of paclitaxel (175 mg/m 2 ; intravenously over 3 h) followed by carboplatin [area under the curve (AUC), 5-7.5 mg/ml/min; intravenously over 1 h] on day 1 of a three-week cycle, and a complete clinical response was achieved. Thereafter, the patient was followed up without any further treatment. Nearly two years after the initial therapy, the patient returned to hospital due to a two-month history of shapeless stool. The patient's cancer antigen (CA)-125 levels were within the normal range (normal range, <35 U/ml), and positron emission tomography-computed tomography (PET-CT) detected metastases of the rectum, with no other positive sites (Fig. 1). Review of the initial histopathology using immunohistochemistry revealed a gr...

show abstract

Transitional cell carcinoma of the ovary (Review)

Cited by 22 publications

References 17 publications

Bilateral Ovarian Transitional Cell Carcinoma

Bilateral Ovarian Transitional Cell Carcinoma

Immunohistological Insight into the Correlation between Neuropilin-1 and Epithelial-Mesenchymal Transition Markers in Epithelial Ovarian Cancer

Good survival in a patient with recurrent transitional cell carcinoma of the ovary: A case report of PET-CT for detection and follow-up

Contact Info

Product

Resources

About